RxDoctor Payments Data

David Wolinsky, MD

Cardiovascular Disease · Weston, FLNPI 1164420998

Payments from drug & device makers

$389,596in general payments, 2019–2025

Across 552 payments — averaging $705.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$157K
  • Astellas Pharma US Inc$90K
  • Akcea Therapeutics, Inc.$69K
  • Bridgebio Pharma, Inc.$35K
  • Alnylam Pharmaceuticals Inc.$30K
  • Whitehall International Inc$3K
  • plus $5K from 16 others

What the payments were for

  • Consulting fees$63,20116%
  • Speaking & faculty fees$261,45867%
  • Travel & lodging$52,79414%
  • Food & beverage$11,2833%
  • Education$8610%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$389,596 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$73,192
Medicare patients
497
Services billed
899

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis260$6,052,908
VyndaqelTafamidis Meglumine29$595,002
EliquisApixaban180$195,635
JardianceEmpagliflozin108$149,438
EntrestoSacubitril/Valsartan91$121,893
Repatha SureclickEvolocumab79$85,320
FarxigaDapagliflozin Propanediol55$55,527
XareltoRivaroxaban25$28,340
Praluent PenAlirocumab42$25,331
Atorvastatin Calcium313$3,709
Rosuvastatin Calcium185$2,206
Metoprolol Succinate160$2,081
Losartan Potassium153$2,042
Ezetimibe124$1,745
Spironolactone112$1,155

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Vyndaqel, Eliquis$157,327$6,843,546469 claims
Boehringer IngelheimJardiance$59$149,438108 claims
NovartisEntresto$1,027$121,89391 claims
AstraZenecaFarxiga$2,549$55,52755 claims
Johnson & JohnsonXarelto$428$28,34025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Weston

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →